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Abstract 
Background 
The lymph node ratio (LNR; number of positive nodes divided by total nodes harvested) has been 
demonstrated to be a prognostic factor in colon cancer, but its role in extraperitoneal rectal cancer is 
still debated; furthermore, no data are available on laparoscopic rectal resection. The aim of this 
study was to evaluate the prognostic impact of LNR on long-term outcomes after laparoscopic total 
mesorectal excision (LTME) for extraperitoneal cancer in consecutive patients with a 5-year 
minimum follow-up. 
Methods 
This study is a prospective analysis of consecutive patients who underwent LTME for 
adenocarcinoma of the extraperitoneal rectum. 
Results 
LTME was performed in 158 patients. The median number of LN harvested was 12 (range = 3–25). 
The proportion of specimens with fewer than 12 examined LN was significantly higher in patients 
who had neoadjuvant chemoradiotherapy (p < 0.001). During a median follow-up period of 122 
months, the local recurrence rate was 8 %. At univariate analysis, disease-free survival and overall 
survival significantly decreased with increasing LNR (p < 0.001). Multivariate analysis showed that 
the distal margin ≤1 cm was the only independent predictor of local recurrence (p = 0.028). LNR 
(cutoff value = 0.25) and lymphovascular invasion were significant prognostic factors for both 
disease-free (p = 0.015 and p = 0.046, respectively) and overall survival (p = 0.031 and p = 0.040, 
respectively). Even in the subgroup of patients in whom fewer than 12 LN were examined, LNR 
confirmed its prognostic role, with a statistical trend toward worse disease-free survival and overall 
survival. 
Conclusion 
Metastatic LNR is an independent prognostic factor for disease-free survival and overall survival 
after LTME for extraperitoneal rectal cancer. 
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Excellence of surgical technique is of particular relevance in the treatment of extraperitoneal rectal 
cancer. Routine excision of the intact mesorectum during resection of cancer of the middle and 
lower rectum has resulted in a significant decrease in local recurrence rates [1]. Developed and 
popularized by Heald and co worker [1], total mesorectal excision (TME) is presently the surgical 
gold standard, with a 4 % local recurrence rate and a 78 % tumor-free survival rate in curative cases 
at 5 years [2]. 
A recent meta-analysis by Huang et al. [3] of randomized controlled trials that included small 
numbers of patients with upper or mid-to-low rectal cancer did not show differences between 
laparoscopic and open surgery in terms of the number of lymph nodes (LN) harvested, local 
recurrence, 3-year disease-free survival, and overall survival. Although a minimum of 12 LN in the 
tumor specimen is recommended for an adequate assessment of tumor staging, the number of 
resected LN after TME is highly variable. 
While the prognostic role of the lymph node ratio (LNR) in colon cancer patients has been 
demonstrated, its role in extraperitoneal rectal cancer is still under debate. Furthermore, no cutoff 
values have been clearly identified, and no prospective data are available in patients who underwent 
laparoscopic TME. 
The aim of this study was to prospectively evaluate the prognostic value of the LNR in consecutive 
patients who underwent laparoscopic TME for extraperitoneal rectal cancer with a 5-year minimum 
follow-up. 
Materials and methods 
The data of all patients admitted to our institution with histologically proven adenocarcinoma of 
extraperitoneal (mid and low) rectum were entered into a prospective database. In the absence of 
specific contraindications to laparoscopy (e.g., severe cardiopulmonary disease and glaucoma), 
patients with tumors in the extraperitoneal rectum were selected for laparoscopic TME based on the 
following criteria: elective surgery, absence of acute intestinal occlusion or perforation, and 
American Society of Anesthesiologists (ASA) status of I–III. Neither morbid obesity nor prior 
pelvic surgery was considered a contraindication to laparoscopic TME. 
The preoperative workup included clinical evaluation, total colonoscopy, chest and upper 
abdominal computed tomography (CT) scan, endoscopic ultrasound and pelvic CT scan until 2003, 
then pelvic magnetic resonance imaging (MRI), and tumor marker assay for carcinoembryonic 
antigen (CEA) and cancer antigen 19-9. 
Neoadjuvant chemoradiotherapy (CRT) was discussed in a multidisciplinary setting. Patients 
preoperatively staged as T3-4 N0-1 without distant metastases received preoperative CRT (45 Gy 
over 4 weeks, together with systemic 5-fluorouracil intravenous infusion) and were reevaluated by 
clinical examination, rigid rectoscopy, endoscopic ultrasound, and CT or MRI 4 weeks after the 
completion of CRT. Definitive inclusion in the study was decided at this point, but patients with T4 
tumors that did not show clinical downstaging or downsizing were excluded as they were 
considered a contraindication to the laparoscopic approach. 
All surgical procedures were performed by surgeons experienced in colorectal and laparoscopic 
advanced surgery. They followed the same oncologic principles as described by Heald and co 
worker [1]: adequate resection margins; en bloc high ligation of the inferior mesenteric artery 
(IMA) and lymphadenectomy; and minimal intraoperative manipulation of the tumor mass. Our 
technique of laparoscopic anterior resection with TME has been previously described [4]. When 
digital examination revealed that the neoplasm reached the anatomic anal canal or was fixed to the 
pelvic floor, a laparoscopic abdominoperineal resection was performed. 
Only patients with a minimum follow-up of 60 months were included in the study. For this 
prospective study, a database was created to contain the patient’s characteristics (age, gender, and 
ASA status), preoperative assessment, operative variables, pathological examination, and short-term 
and long-term outcomes. Operative variables included duration of the operation (from skin incision 
to the application of dressings), intraoperative morbidity and mortality, and conversion rate to 
abdominal surgery. Conversion to laparotomy was defined as an unplanned incision or an incision 
made longer or earlier than planned. Pathological examination included stage of disease (TNM), 
length of the surgical specimen, number of LN harvested, LNR (defined as the number of positive 
nodes divided by total nodes harvested), and longitudinal and radial margins of excision. Lymph 
nodes in the mesorectal fatty tissue were identified after formalin fixation of the specimen. Long-
term outcomes included the local recurrence rate, incidence of abdominal wall and distant 
metastases, disease-free survival, and overall survival for rectal cancer. 
Patients were classified in four groups according to the LN metastases distribution (LND): (1) 
LND0, no LN metastasis; (2) LND1, metastases in the perirectal nodes; (3) LND2, metastases in the 
intermediate nodes; and (4) LND3, metastases in nodes at the origin of the IMA. Stage III patients 
were divided into four categories according to quartiles for the LNR: 0.01–0.10, 0.11–0.25, 0.26–
0.43, and ≥0.44. 
All patients who received neoadjuvant CRT and stage II–III–IV patients were offered an adjuvant 
treatment after a clinical oncologic evaluation within 8 weeks after surgery: 
Follow-up assessment consisted of a digital examination, rectoscopy, and tumor marker assay every 
3 months for the first 2 years, then every 6 months thereafter. A full colonoscopy was performed at 
12 months and then every 3 years, and chest and abdominopelvic CT scans were performed at 6 and 
12 months and every year thereafter. The data were collected prospectively from the time of 
diagnosis. 
Statistical analysis 
Quantitative data are given as median and range and qualitative data as frequency and percentage. 
Patients with a minimum follow-up of 60 months were included in the analysis. Univariate analyses 
of 5-year overall survival and disease-free survival rates were performed using the Kaplan–Meier 
method, and the differences between the groups were analyzed using the log-rank test. Patients’ 
observations were censored on the date of last examination or death. 
A multivariable Cox regression analysis was performed to identify predictive factors of local 
recurrence, disease-free survival, and overall survival using both forward and backward stepwise 
selection. Explanatory variables with univariable P ≤ 0.200 were included in the multivariable 
analysis. This significance level was chosen to incorporate all potentially important predictor 
variables in the final modeling process. All sets of variables were analyzed: age, gender, type of 
surgery, conversion to open surgery, pT stage, tumor grade, number of LN harvested, LNR, LND, 
peritumoral lymphocytic infiltrate, lymphovascular invasion, distal resection margins, postoperative 
anastomotic leakage, neoadjuvant treatment, and postoperative treatment. A level of 5 % was set as 
the criterion for statistical significance. The data were collected in an Excel spreadsheet. The 
statistical analysis was performed using SYSTAT ver. 10 (Systat Software, Inc., Chicago, IL, 
USA). 
Results 
Between July 1996 and July 2006, 158 patients with extraperitoneal rectal adenocarcinoma 
underwent laparoscopic TME (Table 1). One hundred twenty-six (79.7 %) patients underwent a 
“sphincter-saving” procedure and 32 (20.3 %) underwent abdominoperineal resection. There were 
21 (13.3 %) conversions to laparotomy. The 30-day postoperative morbidity rate was 22.2 % 
(35/158). The reoperation rate was 7.6 % (12/158). The 30-day mortality rate was 0.6 % (1/158). 
Table 1  
Baseline characteristics 
  Laparoscopic TME (n = 158) 
Gender 
 Male [n (%)] 94 (59.5) 
Age (years) 
 Median (range) 68 (28–90) 
ASA status [n (%)] 
  Laparoscopic TME (n = 158) 
 I 41 (26.0) 
 II 83 (52.5) 
 III 34 (21.5) 
Type of surgical procedure [n (%)] 
 Anterior resection 126 (79.7) 
 Abdominoperineal resection 32 (20.3) 
Conversion to open surgery [n (%)] 21 (13.3) 
 Locally advanced neoplasm 12 (7.6) 
 Difficult exposure 5 (3.1) 
 Difficult in transecting the distal rectum 2 (1.3) 
 Obesity 2 (1.3) 
Postoperative complications [n (%)] 35 (22.2) 
 Anastomotic leakage 17 (12.5) 
 Wound infection 7 (4.4) 
 Prolonged ileus 6 (3.8) 
 Urinary tract infection 3 (1.9) 
 Pulmonary infection 2 (1.3) 
Postoperative mortality [n (%)] 1 (0.6) 
 Intestinal infarction 1 
Tumor grading [n (%)] 
 G1 52 (32.9) 
 G2 78 (49.4) 
 G3 28 (17.7) 
Tumor staging [n (%)] 
 I 48 (30.4) 
 II 38 (24.1) 
 III 50 (31.6) 
 IV 22 (13.9) 
Distal margin [n (%)] 
 ≤1 cm 30 (24.1) 
 >1 cm 128 (75.9) 
Circumferential margin [n (%)] 
 Positive 0 (0) 
 Negative 158 (100) 
Number of lymph nodes harvested (n) 
 Median (range) 12 (3–25) 
Peritumoral lymphocytic infiltrate [n (%)] 
  Laparoscopic TME (n = 158) 
 Negative 68 (43) 
 Positive 90 (57) 
Lymphovascular invasion [n (%)] 
 Negative 85 (53.8) 
 Positive 73 (46.2) 
Neoadjuvant chemoradiotherapy [n (%)] 35 (22.2) 
Adjuvant treatment [n (%)] 
 Chemotherapy 72 (48) 
 Chemoradiotherapy 16 (10.7) 
TME total mesorectal excision 
Anatomopathological results 
The clearance of the distal margin was ≤1 cm in 30 (18.9 %) cases, with no distal margin tumor 
infiltration. All circumferential margins were clear. The rectal cancer stages, according to the 7th 
AJCC TNM staging system, for the 158 patients were stage I in 48 patients, stage II in 38, stage III 
in 50, and stage IV in 22. The median number of LN harvested was 12 (range = 3–25). The 
proportion of specimens with fewer than 12 examined LN was significantly higher in the group of 
35 patients who underwent neoadjuvant CRT (77.1 vs. 40.7 %; p < 0.001). Furthermore, the median 
number of LN harvested was lower in stage I–II patients (n = 10.5) than in stage III patients 
(n = 11) (p = 0.079). Among the stage III patients, there was a higher percentage of pN2 in the 
group with more than 12 LN in the surgical specimen (40 vs. 20 %; p = 0.100). LN metastases were 
distributed among the stage I–III patients as follows: 86 patients were in the LND0 group, 35 in 
LND1, 13 in LND2, and 2 in LND3. 
Long-term results 
The median follow-up period was 122 months (range = 60–180). Seven (4.4 %) patients were lost 
to follow-up (4 stage I and 3 stage II). A total of 72 (48 %) patients received adjuvant chemotherapy 
and 16 (10.7 %) adjuvant CRT. The local recurrence rate was 8 % (12/150) at a median time of 24.5 
months (range = 10–56). 
The distribution of stages was similar between the group of patients with local recurrence (LR 
group) and the group of patients who did not experience a local recurrence (non-LR group): stage I: 
25 % (n = 3) versus 29.7 % (n = 41), p = 0.989; stage II: 33.3 % (n = 4) versus 22.5 % (n = 31), 
p = 0.618; stage III: 33.3 % (n = 4) versus 33.3 % (n = 46), p = 0.750; stage IV: 8.4 % (n = 1) 
versus 14.5 % (n = 20), p = 0.876. A significantly higher rate of patients with fewer than 12 LN was 
found in the LR group than in the non-LR group (83.3 vs. 42.2 %, p = 0.014). Both groups did not 
differ in terms of use of neoadjuvant CRT (33.3 vs. 21 %, p = 0.532). 
Distant metastases developed in 23 (17.8 %) stage I–III patients. The port-site metastases rate was 
1.3 % (2/150), involving a stage IV patient 17 months after surgery and a stage III patient 28 
months after surgery. 
The 5-year overall survival rate was 69.8 % and the disease-free survival rate was 60.5 %. The 5-
year overall survival rate was 92.3 % for stage I patients, 85.6 % for stage II, and 63.1 % for stage 
III; no patient with stage IV disease was alive at 41 months after surgery (p < 0.001). The 5-year 
disease-free survival rate was 86.5 % for stage I patients, 75.6 % for stage II, and 48.4 % for stage 
III; no patient with stage IV was disease-free at 41 months after surgery (p < 0.001). 
Excluding the stage IV patients, univariate analysis showed that for the risk of local recurrence 
(Table 2), tumor grade (p = 0.006), lymphovascular invasion (p = 0.010), distal surgical margins 
≤1 cm (p = 0.018), and number of LN harvested (p = 0.050) were all statistically significant, while 
pT stage and neoadjuvant CRT showed a statistical trend (p = 0.111 and p = 0.085, respectively). 
Multivariate analysis indicated distal surgical margins ≤1 cm as an independent predictor of local 
recurrence (p = 0.028), while the number of LN harvested (p = 0.087), tumor grade (p = 0.052), and 
pT stage (p = 0.100) had a statistical trend. 
Table 2  
Univariate and multivariate analyses of risk factors for local recurrence after laparoscopic total 
mesorectal excision 
Univariate analysis Multivariate analysis 
  N = 129 Hazard ratio (95% 
CI) P† 
Hazard ratio (95% 
CI) P† 
Age (years) 
 >68 57 1       
 ≤68 72 0.647 (0.187–2.237) 0.491     
Gender 
 Female 55 1       
 Male 74 1.358 (0.377–4.889) 0.639     
Type of surgical procedure 
 Abdominoperineal 
resection 27 1       
 Anterior resection 102 1.149 (0.233–5.670) 0.865     
Conversion to open surgery 
 No 115 1       
 Yes 14 1.981 (0.383–10.258) 0.415     
pT stage 
 T1–T2 57 1   1   
 T3 72 3.600 (0.745–17.390) 0.111 4.753 (0.629–35.913) 0.100 
Tumor grade 
 G1-2 103 1   1   
 G3 26 6.346 (1.695–23.760) 0.006 6.197 (0.981–39.155) 0.052 
Number of lymph nodes harvested 
 ≥12 61 1   1   
 <12 68 4.853 (1.001–23.533) 0.050 4.202 (0.986–31.739) 0.087 
Lymph node ratio 
 0 79 1       
 0.01–0.25 26 1.411 (0.248–3.505) 0.676     
 >0.25 24 2.057 (0.548–7.725) 0.277     
Lymph node distribution 
Univariate analysis Multivariate analysis 
  N = 129 Hazard ratio (95% 
CI) P† 
Hazard ratio (95% 
CI) P† 
 0 86 1       
 1 35 1.136 (0.823–1.415) 0.453     
 2 + 3 15 1.028 (0.323–1.721) 0.301     
Peritumoral lymphocytic infiltrate 
 Present 75 1       
 Poor/absent 54 2.080 (0.365–11.865) 0.410     
Lymphovascular invasion 
 Absent 69 1   1   
 Present 60 5.775 (1.533–21.758) 0.010 2.931 (0.509–16.888) 0.229 
Distal surgical margin (cm) 
 >1 99 1   1   
 ≤1 30 4.650 (1.307–16.538) 0.018 6.586 (1.222–21.442) 0.028 
Postoperative anastomotic leakage 
 No 119 1       
 Yes 10 1.222 (0.140–10.652) 0.856     
Neoadjuvant treatment 
 No 96 1   1   
 Yes 33 3.206 (0.851–12.086) 0.085 2.698 (0.454–16.018) 0.275 
Adjuvant treatment 
 No 41 1       
 Yes 88 2.141 (0.541–8.472) 0.278     
95% CI 95% confidence interval 
†Stepwise logistic regression analysis 
At univariate analysis, the factors associated with a poorer disease-free survival and overall survival 
(Table 3, 4) were age, pT stage, tumor grade, number of LN harvested, LNR, lymphovascular 
invasion, peritumoral lymphocytic infiltrate, and postoperative treatment. Both 5-year disease-free 
survival and overall survival significantly decreased with increasing LNR (p < 0.001) (Figs. 1, 2). 
At multivariate analysis, tumor grade (p = 0.007), LNR > 0.25 (p = 0.015), and lymphovascular 
invasion (p = 0.046) were significant predictors of poorer disease-free survival (Table 3), while pT 
stage (p = 0.088), number of LN harvested (p = 0.174), and peritumoral lymphocytic infiltrate 
(p = 0.168) showed a statistical trend. For overall survival, the only independent factors were LNR 
>0.25 (p = 0.031) and lymphovascular invasion (p = 0.040), while tumor grade showed a statistical 
trend (p = 0.091) (Table 4). 
Table 3  
Univariate and multivariate analyses of risk factors for disease-free survival after laparoscopic total 
mesorectal excision 
  Univariate analysis Multivariate analysis 
  
N = 129 Hazard ratio (95% CI) P† 
Hazard ratio (95% 
CI) P† 
  Univariate analysis Multivariate analysis 
  
N = 129 Hazard ratio (95% CI) P† 
Hazard ratio (95% 
CI) P† 
Age (years) 
 >68 57 1   1   
 ≤68 72 2.039 (0.917–4.535) 0.081 1.452 (0.238–8.871) 0.686 
Gender 
 Female 55 1       
 Male 74 0.991 (0.459–2.137) 0.981     
Type of surgical procedure 
 Abdominoperineal 
resection 27 1       
 Anterior resection 102 0.568 (0.230–1.404) 0.221     
Conversion to open surgery 
 No 115 1       
 Yes 14 2.056 (0.661–6.402) 0.213     
M 
 T1–T2 57 1   1   
 T3 72 4.578 (1.825–11.484) 0.001 4.122 (0.775–23.198) 0.088 
Tumor grade 
 G1-2 103 1   1   
 G3 26 16.917 (4.986–27.392) <0.001 15.565 (5.655–32.329) 0.007 
Number of lymph nodes harvested 
 ≥12 61 1   1   
 <12 68 2.277 (1.020–5.083) 0.045 2.533 (0.613–10.468) 0.174 
Lymph node ratio 
 0 79 1   1   
 0.01–0.25 26 3.173 (1.181–8.528) 0.0280 2.856 (0.988–9.112) 0.063 
 >0.25 24 7.108 (2.599–19.436) <0.001 6.523 (2.347–20.010) 0.015 
Lymph node distribution 
 0 86 1       
 1 35 1.536 (0.823–2.415) 0.453     
 2 + 3 15 2.088 (0.897–3.721) 0.301     
Peritumoral lymphocytic infiltrate 
 Present 75 1   1   
 Poor/absent 54 2.582 (0.957–6.967) 0.061 1.279 (0.146–1.696) 0.168 
Lymphovascular invasion 
 Absent 69 1   1   
 Present 60 7.500 (2.726–20.636) <0.001 2.247 (1.166–8.922) 0.046 
  Univariate analysis Multivariate analysis 
  
N = 129 Hazard ratio (95% CI) P† 
Hazard ratio (95% 
CI) P† 
Distal surgical margin (cm) 
 >1 99 1       
 ≤1 30 0.865 (0.345–2.167) 0.757     
Postoperative anastomotic leakage 
 No 119 1       
 Yes 10 1.758 (0.466–6.626) 0.405     
Neoadjuvant treatment 
 No 96 1   1   
 Yes 33 1.978 (0.763–5.128) 0.161 1.849 (0.313–10.928) 0.556 
Adjuvant treatment 
 No 41 1   1   
 Yes 88 7.771 (2.782–21.707) <0.001 4.225 (0.706–25.282) 0.109 
95% CI 95% confidence interval 
†Stepwise logistic regression analysis 
Table 4  
Univariate and multivariate analyses of risk factors for overall survival after laparoscopic total 
mesorectal excision 
  Univariate analysis Multivariate analysis 
  
N = 129 Hazard ratio (95% CI) P† 
Hazard ratio (95% 
CI) P† 
Age (years) 
 >68 57 1   1   
 ≤68 72 3.333 (1.239–8.971) 0.017 2.004 (0.187–8.510) 0.696 
Gender 
 Female 55 1       
 Male 74 0.856 (0.361–2.029) 0.723     
Type of surgical procedure 
 Abdominoperineal 
resection 27 1   1   
 Anterior resection 102 0.373 (0.143–0.976) 0.045 0.513 (0.052–5.088) 0.568 
Conversion to open surgery 
 No 115 1       
 Yes 14 1.103 (0.284–4.278) 0.888     
pT stage 
 T1–T2 57 1   1   
 T3 72 3.883 (1.359–11.094) 0.011 2.129 (0.183–24.806) 0.546 
Tumor grade 
  Univariate analysis Multivariate analysis 
  
N = 129 Hazard ratio (95% CI) P† 
Hazard ratio (95% 
CI) P† 
 G1-2 103 1   1   
 G3 26 7.750 (2.574–23.336) <0.001 8.116 (0.718–34.698) 0.091 
Number of lymph nodes harvested 
 ≥12 61 1   1   
 <12 68 2.295 (0.915–5.757) 0.077 1.740 (0.274–11.071) 0.557 
Lymph node ratio 
 0 79 1   1   
 0.01–≤0.25 26 3.789 (1.184–12.123) 0.039 3.061 (0.929–12.251) 0.085 
 >0.25 24 10.286 (3.375–31.353) <0.001 9.178 (1.288–30.258). 0.031 
Lymph node distribution 
 0 86 1       
 1 35 1.986 (0.912–2.915) 0.298     
 2 + 3 15 2.874 (0.822–3.166) 0.211     
Peritumoral lymphocytic infiltrate 
 Present 75 1   1   
 Poor/absent 54 4.857 (1.285–18.355) 0.020 1.536 (0.659–5.580) 0.696 
Lymphovascular invasion 
 Absent 69 1   1   
 Present 60 31.571 (6.400–55.745) <0.001 7.580 (1.100–52.235) 0.040 
Distal surgical margin (cm) 
 >1 99 1       
 ≤1 30 0.531 (0.167–1.686) 0.283     
Postoperative anastomotic leakage 
 No 119 1       
 Yes 10 1.807 (0.434–7.529) 0.416     
Neoadjuvant treatment 
 No 96 1       
 Yes 33 1.650 (0.574–4.746) 0.353     
Adjuvant treatment 
 No 41 1   1   
 Yes 88 7.967 (2.253–28.174) <0.001 7.904 (0.274–25.327) 0.228 
95% CI 95% confidence interval 
†Stepwise logistic regression analysis 
 Fig. 1  
Overall survival according to lymph node ratio (LNR); P < 0.001, Log rank test 
 
Fig. 2  
Disease-free survival according to lymph node ratio (LNR); P < 0.001, Log rank test 
Univariate and multivariate analyses were also carried out for the 69 stage I–III patients in whom 
fewer than 12 LN were examined. Even in the analysis of this subgroup, the LNR >0.25 confirmed 
its prognostic role for both disease-free survival (p = 0.004 and p = 0.144 at univariate and 
multivariate analyses, respectively) and overall survival (p = 0.001 and p = 0.155, respectively). 
No statistically significant differences were observed for 5-year disease-free survival and overall 
survival rates between the 19 stage II patients with fewer than 12 LN and the 50 stage III patients 
(p = 0.245 and p = 0.563, respectively). 
Discussion 
Evidence-based data support the use of laparoscopic surgery for colon cancer [5–7], whereas data 
on laparoscopic TME with or without a sphincter-saving procedure are limited [8, 9]. Evidence 
comes mainly from several case series [4, 10–12], comparative nonrandomized studies [13–15], or 
randomized clinical trials (RCTs) [16–21] with a limited number of patients or a relatively short 
follow-up period. 
A recent meta-analysis by Huang et al. [3] to assess the oncologic adequacy of resection and the 
oncologic outcomes after laparoscopic versus open surgery for rectal cancer showed that 
laparoscopic surgery is comparable to open surgery in terms of anatomopathological findings and 
the local recurrence rate, although no data about the prognostic role of lymphadenectomy were 
given. To our best knowledge, no clinical trials have analyzed the risk factors for local recurrence, 
disease-free survival, and overall survival after laparoscopic TME for extraperitoneal rectal cancer 
over a 5-year minimum follow-up period. 
Among the pathological variables associated with oncologic outcome, the number of LN examined 
in the specimen plays a key role. Accurate pathological staging of colorectal cancer is essential in 
stage I–III patients in order to select those who might benefit from adjuvant treatment, and it relies 
on the identification of lymph node metastases [22]. A systematic review by Chang et al. [23] 
showed that survival improved as the number of examined LN increased in patients with stage II 
and III colon cancer. The National Institute of Clinical Excellence (NICE) Colorectal Cancer 
Guidance and the American Joint Committee on Cancer (AJCC) have recommended that a median 
of 12 LN should be examined in patients operated on with curative intent-to-treat colorectal cancer 
[24, 25]..Nevertheless, the number of metastatic LN is related not only to the depth of tumor wall 
invasion, but also on the number of LN examined [26–28], which, in turn, varies depending on 
several other factors, including patient-related variables (age, gender, body mass index), tumor-
related variables (size, stage, and grade), the surgeon, and the pathologist [29]. 
Preoperative CRT leads to a significantly reduced number of LN for examination in the tumor 
specimen [30–34]. It is associated with lymphocyte depletion in the LN and with tissue fibrosis, 
which makes the LN smaller and more difficult to be identified. We have observed that the 
proportion of specimens with fewer than 12 examined LN was significantly higher in the group of 
patients who had neoadjuvant CRT (77.1 vs. 40.7 %; p < 0.001). In addition, a higher rate of 
patients with fewer than 12 LN was found in the group of patients who experienced a local 
recurrence. Because of the increasing use of neoadjuvant CRT in clinical practice, we believe that 
the LN status in patients who undergo preoperative treatment should be considered with caution. 
Several studies on open surgery have demonstrated that tumor stage is related to the number of LN 
and vice versa [35–38]. A higher number of LN retrieved in the surgical specimen increases the 
probability of metastatic LN; therefore, patients with stage III rectal cancer might have a higher 
average number of LN examined than do stage I–II patients [28, 39]. In our study, we observed that 
the median number of LN harvested was lower in stage I–II patients than in stage III patients 
(p = 0.079). Furthermore, among the stage III patients, there was a higher percentage of pN2 in the 
group of patients with more than 12 LN in the surgical specimen (p = 0.100). 
The metastatic LNR, which was initially proposed for patients with esophageal and gastric cancer 
[40, 41], is expected to yield a more reliable prognosis. Several recent studies have investigated the 
role of the LNR in colorectal cancer; however, few reported on rectal cancer and none on 
laparoscopic resection. Ceelen et al. [42], in a systematic review of the prognostic value of the LNR 
in stage III colorectal cancer, stated that it is a stronger prognostic factor than the number of LN for 
both colon and rectal cancer patients. All identified studies about rectal cancer [43–50] showed that 
the LNR is an independent predictor of overall survival and disease-free survival. In particular, 
Rosenberg et al. [46] in 1,263 rectal cancer patients over a 25-year time period and Peschaud et al. 
[47] in 307 patients with high, mid, or low rectal cancer reported LNR as an independent prognostic 
factor, even when fewer than 12 LN were examined. Nevertheless, several limitations apply to the 
interpretation of the results of these studies: most did not separately analyze intra- and 
extraperitoneal rectal cancer patients [43, 46, 47], and some included only upper rectal cancer 
patients [50], had a median follow-up period of less than 5 years [45, 47–50], did not report data 
regarding the surgical technique used [43, 49], or included patients operated on before the 
introduction of TME [43, 46]. Moreover, different cutoff values for LNR were proposed based 
mainly on quartiles classification rather than a single value. 
To the best of our knowledge, this is the first prospective study to evaluate the role of 
lymphadenectomy and LNR as prognostic factors after laparoscopic TME for extraperitoneal rectal 
cancer over a median follow-up period of 122 months. In line with other studies [44], our univariate 
and multivariate analyses showed that a cutoff of 12 LN retrieved in the specimen is a prognostic 
factor for patients with rectal cancer. We observed a statistical trend toward a higher risk of local 
recurrence and a worse disease-free survival among patients with fewer than 12 LN harvested. 
Furthermore, no statistically significant differences were observed in terms of 5-year disease-free 
survival and overall survival rates between stage II patients with fewer than 12 LN and stage III 
patients (p = 0.245 and p = 0.563, respectively), confirming that a minimum of 12 LN may be 
mandatory to correctly identify node-negative cancers. 
At univariate analysis, both 5-year disease-free survival and overall survival significantly decreased 
with increasing LNR. At multivariate analysis, LNR >0.25 was an independent factor for worse 
disease-free (p = 0.015) and overall survival (p = 0.031). The univariate and multivariate analyses 
carried out for the 69 stage I–III patients with fewer than 12 LN harvested confirmed the prognostic 
role of the LNR for both disease-free survival (p = 0.004 at univariate analysis and p = 0.144 at 
multivariate analysis) and overall survival (p = 0.001 and p = 0.145, respectively). Our results 
compare favorably with those reported by Rosenberg et al. [46] and Peschaud et al. [47], which 
demonstrated that the LNR they identified was of prognostic relevance independent of the number 
of resected LN. 
Finally, Huh et al. [51] recently reported LND as an independent predictor of survival in 1,205 
consecutive patients who underwent potentially curative surgery for sigmoid colon or rectal cancer 
with high ligation of the inferior mesenteric artery. In our series, LND did not show a statistically 
significant role. 
In conclusion, our prospective study highlights the prognostic role of the LNR cutoff value of 0.25 
in patients who underwent laparoscopic TME for extraperitoneal rectal cancer, over a long follow-
up period. Further prospective large trials are needed to define the LNR cutoff to be used with the 
TNM staging system and the prognostic significance of LND. 
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